<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5A5739A5-B58F-47C1-B425-94267E91DEE1"><gtr:id>5A5739A5-B58F-47C1-B425-94267E91DEE1</gtr:id><gtr:name>Technology Strategy Board</gtr:name><gtr:address><gtr:line1>Block B, Floor 1</gtr:line1><gtr:line2>North Star House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1JF</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A5739A5-B58F-47C1-B425-94267E91DEE1"><gtr:id>5A5739A5-B58F-47C1-B425-94267E91DEE1</gtr:id><gtr:name>Technology Strategy Board</gtr:name><gtr:address><gtr:line1>Block B, Floor 1</gtr:line1><gtr:line2>North Star House</gtr:line2><gtr:line3>North Star Avenue</gtr:line3><gtr:line4>Swindon</gtr:line4><gtr:postCode>SN2 1JF</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8491E54C-A18D-48A8-9C16-13F1620FC665"><gtr:id>8491E54C-A18D-48A8-9C16-13F1620FC665</gtr:id><gtr:firstName>Zahid</gtr:firstName><gtr:surname>Latif</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_G1000732"><gtr:id>74C2D3CA-D572-4F4C-B7F3-5D49D06C7E38</gtr:id><gtr:title>SC4SM Phase 1</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_G1000732</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Stem Cells for Safer Medicines is a public-private collaboration whose objective is to enable the creation a bank of stem cells, open protocols and standardised systems in stem cell technology that will enable consistent differentiation of stem cells into stable homogenous populations of particular cell types, with physiologically relevant phenotypes suitable for toxicology testing in high throughput platforms. The collaboration will draw upon scientific expertise within pharmaceutical companies - especially in relation to safety assessment of new medicines - academic stem cell experts in the UK and seek engagement with third parties including biotechnology companies. Stem Cells for Safer Medicines is therefore interested in the potential of differentiating human stem cells into normal human cells, such as those in the liver (hepatocytes) and heart muscle (cardiomyocytes) for use in the early, high throughput, toxicology screening of potential new medicines. However, substantive scientific hurdles remain that are best tackled by a public-private collaboration.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>160001</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0BA66A0C-3F97-468E-9B1A-50E8F48172DE</gtr:id><gtr:title>Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening.</gtr:title><gtr:parentPublicationTitle>Stem cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9ba1569cd98c74f7d57fc9f3abdeef5"><gtr:id>f9ba1569cd98c74f7d57fc9f3abdeef5</gtr:id><gtr:otherNames>Baxter MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1873-5061</gtr:issn><gtr:outcomeId>pm_16660_20_20483202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26A05F4A-0E04-40F0-8915-12624B2874EF</gtr:id><gtr:title>A novel chemically directed route for the generation of definitive endoderm from human embryonic stem cells based on inhibition of GSK-3.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a0f52cb361ddb376b90cccb201479f0"><gtr:id>9a0f52cb361ddb376b90cccb201479f0</gtr:id><gtr:otherNames>Bone HK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_16660_20_21610099</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_G1000732</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>